INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders that are characterized by ineffective hematopoiesis, resulting in different types of peripheral blood cytopenias. 1 Because of the large variability of the disease course, outcome prediction at the time of clinical presentation is critical and decision making is challenging. 2 Therefore, the scientific community has historically made major efforts to develop risk scoring systems that would help clinicians to adopt personalized treatment strategies. 3 In routine practice, one of the most widely used prognostic indices at the time of diagnosis is the International Prognostic Scoring System (IPSS), [3] [4] [5] which was developed for untreated patients, and its use is recommended by major international guidelines. 1 This index is based on the following laboratory data: percentage of bone marrow blasts, number of peripheral cytopenias, and cytogenetic abnormalities. Based on the scores from these 3 broad disease variables, patients are assigned to 4 risk groups with distinct overall survival (OS): low-risk, intermediate-1, intermediate-2, and high-risk MDS. 5 Patients classified in these latter 2 groups (ie, those with advanced disease) at the time of diagnosis have poor life expectancy, 4 making accurate prediction of OS a critical issue for optimal clinical management.
However, the IPSS is not dynamic and is meant to be applied only at the time of diagnosis. Moreover, it is less able to distinguish the 2 highest groups from one another, especially for patients who have received prior treatment. Given that affected patients often are of advanced age, the difference might suggest aggressive treatment versus supportive care among those with advanced disease. Therefore, there is a critical need to further increase prognostic accuracy among patients with IPSS intermediate-2 and high-risk MDS.
In a previous study, we demonstrated that patients' self-reported fatigue provides independent prognostic information for OS in newly diagnosed patients with advanced MDS. 6 These data have laid the groundwork for further investigation regarding how the inclusion of self-reported fatigue could be implemented into already existing prognostic models to possibly improve survival prediction. 7 Within the last decade, there has been mounting evidence that patient-reported outcomes (PROs), including self-reported symptoms, provide prognostic information for survival above and beyond traditional disease factors. [8] [9] [10] [11] [12] [13] However, to the best of our knowledge, studies in this area have been confined to descriptive data analysis and the clinical implication of this evidence has been challenged. 14 The main objective of the current study was to develop a patient-centered prognostic index for patients with advanced MDS to be used in the clinic. We aimed to do this by incorporating self-reported fatigue into the well-established IPSS classification for patients with advanced disease. With the goal of clinical usefulness, and understanding that many patients with advanced disease as seen in the clinic having received prior treatments, the secondary objective of the current study was to investigate whether this new index could enhance the predictive accuracy of IPSS in an independent cohort that included pretreated patients.
MATERIALS AND METHODS

International Development Cohort
The development cohort resulted from an international prospective observational study of patients with newly diagnosed MDS from 37 centers in 9 countries. The primary outcome was the investigation of the value of patients' self-reported fatigue severity as a predictor of OS, and the results were published elsewhere. 6 Herein, we report the results of a prespecified additional aim of the research protocol, namely the development of a patientcentered prognostic index.
Adult patients diagnosed with MDS with an IPSS risk score of intermediate-2 or high-risk (ie, advanced disease) within 6 months before the date of registration were eligible. At baseline (ie, before treatment for advanced disease other than supportive therapy with transfusions [ie, untreated patients]), all patients were asked to complete a health-related quality-of-life (HRQOL) assessment and could be enrolled regardless of the type of therapy that they might receive after baseline evaluation. Additional details have been previously reported. 6, 15 All patients provided written informed consent and the study was approved by the ethics committees of each participating center. The study was conducted in accordance with the Declaration of Helsinki and registered at ClinicalTrials. gov (ClinicalTrials.gov identifier NCT00809575).
Independent Validation Cohort
Patients for the independent cohort were taken from a database maintained at the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts. This overall cohort has been described elsewhere. 16, 17 None of these patients was part of the development cohort. Briefly, beginning in 2006, adult patients with biopsy-confirmed MDS presenting for initial evaluation at DFCI (hereafter denoted as "baseline" for the DFCI cohort) were eligible for enrollment into the Dana-Farber/Harvard Cancer Center MDS Clinical Research Information System database; 85% of eligible patients consented to enrollment. Starting in 2011, an ongoing effort was made to enrich the database for patients with higher risk disease. 18 19 an internationally validated HRQOL questionnaire suitable for use with a generic cancer population. The EORTC QLQ-C30 is a 30-item questionnaire comprising 5 function scales (physical, role, emotional, cognitive, and social), 3 symptom scales (fatigue, nausea/ vomiting, and pain), 6 single-item scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a global health status scale. The EORTC QLQ-C30 scores were calculated using the recommended EORTC procedures. 20 Based on previous evidence demonstrating that fatigue is a major concern for patients with MDS, 21 we defined in the development protocol a priori that the fatigue scale would be regarded as the primary HRQOL outcome for OS prognostic factor analysis. In addition, in our development cohort, fatigue was found to demonstrate the highest prognostic value for OS compared with all other EORTC QLQ-C30 outcomes (data not shown). Instructions regarding how we scored the fatigue scale are available in Supporting Information Table 1 .
Statistical Analysis
Definitions and methods OS was measured from the date of diagnosis (development cohort) or date of initial evaluation at DFCI (independent validation cohort) up to death from any cause. Patients were censored at the date of their last follow-up if they were not dead at the time of analysis. Univariate and multivariable Cox proportional hazards regression analyses were performed to estimate hazard ratios (HRs) with 95% confidence intervals (95% CIs). The log-rank test was used to assess differences in Kaplan-Meier survival curves by risk groups. The predictive performance of the new prognostic index was assessed with both discrimination, using the Harrell C-index, 22 and calibration. Model fit of the prognostic index was assessed by Akaike information criterion (AIC). Statistical significance for all tests was set as 2-sided a 5 .05.
Identification of the prognostic index and sensitivity analyses
A fatigue threshold defining 4 risk groups was chosen that provided both the highest predictive performance for OS and the smallest possible heterogeneity between risk groups. Based on this threshold, a final prognostic index was identified defining 3 risk categories. Kruskal-Wallis and Fisher exact tests were performed to investigate possible differences in baseline sociodemographic and clinical characteristics by the 3 risk groups. In addition, a bootstrap resampling procedure 23 was run to assess the robustness of the novel index, based on stepwise selection of a Cox proportional hazards multivariable model controlling for key confounding variables (5000 resamples).
Internal and external validation
Discrimination and calibration were evaluated for both the development (internal validation) and independent application (external validation) data sets. Calibration was evaluated by estimating the standardized incidence ratio (SIR) and performing a goodness-of-fit chi-square test for the effect of risk group, using a Poisson regression modelbased approach. 24 SIR is the percentage of observed out of expected events from the prognostic index, with a value equal to 1 indicating the best performance. For external validation, calibration was evaluated by comparing the risk-stratified Kaplan-Meier survival estimates between data sets. All analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina). According to the new FA-IPSS(h) index, patients were categorized into 3 groups: risk-1 (123 patients), risk-2 (127 patients), and risk-3 (30 patients). Details regarding how we defined these categories are reported in Supporting Information Table 2 .
RESULTS
OS According to the New FA-IPSS(h) Index
After reclassification of patients from the development cohort into the FA-IPSS(h) index, survival analyses were performed. Patients with the most favorable prognosis (risk-1) were found to have a median OS of 23 months (95% CI, 19-29 months), whereas those with risk-2 had a median OS of 16 months (95% CI, 12-17 months) and those with the least favorable prognosis (risk-3) had a median OS of 10 months (95% CI, 4-13 months). In contrast, the median OS times were 20 months (95% CI, 17-24 months) and 13 months (95% CI, 9-16 months), respectively for patients with IPSS intermediate-2 and high-risk scores. 6 Survival curves of the 3 risk group categories of the new FA-IPSS(h) index and those of the traditional IPSS are depicted in Figures 1A and 1B , respectively. In univariate analysis, the risk-2 and risk-3 categories of the FA-IPSS(h) index were found to be significantly associated with a shorter OS compared with risk-1 (ie, the lowest risk category Original Article months, 1 year, and 2 years were markedly different among the 3 groups (Table 2) .
Internal Validation and Calibration
The Harrell C-index for FA-IPSS(h) was 0.610 in comparison with 0.565 for the IPSS, indicating an important improvement in discriminatory ability. The SIR was equal to 1 overall and for each FA-IPSS(h) index group category, which demonstrated optimal calibration performance. In addition, the group-based goodness-of-fit tests indicated that observed and predicted events were not statistically different among FA-IPSS(h) risk groups.
Sensitivity Analyses
Sociodemographic and clinical characteristics by novel risk group categories are reported in Table 3 . In multivariable analysis, the FA-IPSS(h) risk categories remained the only baseline variable independently associated with OS ( Table 4 ). The FA-IPSS(h) risk-2 and risk-3 categories were simultaneously selected in 85.9% of the bootstrapgenerated multivariable models (4294 of 5000 models), thus confirming their independent prognostic value.
External Application of the FA-IPSS (h) in an Independent Cohort Including Pretreated Patients
The median age of patients in the independent cohort was 68 years, and 67% were male. It is important to note that 24% of these patients received a hypomethylating agent during the month before treatment (see Supporting Information Table 3 ). At a median follow-up of 13 months, we observed 124 deaths. Applying the FA-IPSS(h) definition to these data, 52%, 41%, and 7% of patients, respectively, were classified as risk-1, risk-2, and risk-3. The median OS in the independent cohort data by FA-IPSS(h) risk was similar to that of the development cohort for each of the 3 risk groups, indicating good external calibration. Patterns of OS throughout 2 years also were found to be distinct between risk groups as in the development cohort of untreated patients (Table 2) , with one exception: the 2-year OS was similar for the FA-IPSS(h) risk-3 and risk-2 categories. In this regard, we performed additional analyses to assess possible systematic differences in baseline characteristics and risk classification between pretreated (46 patients) and untreated (143 patients) patients (see Supporting Information Table 3 ). We also investigated OS patterns through 2 years by these 2 groups (see Supporting Information Table 4 ). Overall, these results suggested that an association between FA-IPSS(h) and survival was not confounded by prior treatment in the independent cohort.
Although the FA-IPSS(h) was significantly associated with OS (P 5 .026), the IPSS index was not (P 5 .472) within the data from the independent cohort (see Supporting Information Fig. 1 ). Correspondingly, 
DISCUSSION
We developed the FA-IPSS(h) index, a novel patientcentered prognostic index for individuals with advanced MDS, by including patient's self-reported fatigue into a well-established and widely used disease prognostic index (ie, the IPSS). It is important to note that this new index enhanced survival prediction in both the development and independent cohorts by making a more refined distinction among subgroups of patients. This finding has major clinical implications considering the importance of OS prediction in patients with advanced MDS.
The better stratification of patients that results from using the FA-IPSS(h) index may improve the clinical management of patients in routine practice. For example, it might be helpful in the management of the most vulnerable patients by improving timely palliative care referrals. Indeed, previous studies of patients with other advanced cancers, who have median survival rates similar to those of the study population, have demonstrated that the early integration of palliative care with standard oncologic care resulted in better HRQOL outcomes as well as improved survival. 25 Conversely, the FA-IPSS(h) also might guide clinicians in the early identification of patients with favorable prognosis who can benefit the most from more aggressive therapies.
Implementation of this index in standard practice also might have important implications for eliciting more active patient participation during initial consultations. Unlike other prognostic tools currently used for patients with MDS, use of the FA-IPSS(h) index requires clinicians to engage patients by asking them to briefly selfassess their fatigue severity. Considering the importance of engaging patients in shared decision making 26 and that patient-physician communication in patients with advanced hematologic cancers often is challenging, 27 it will be important to evaluate in future studies whether the use of this novel index also might facilitate patientcenteredness in treatment decisions.
Historically, prognostic tools in oncology have not considered PROs, such as self-reported symptoms, but rather laboratory and pathologic markers related to disease progression. However, there currently is ample evidence indicating that patient-reported symptoms provide clinically meaningful information that suitably complements such traditional clinical data. 28 Using the same questionnaire used in the current study with a large cohort of patients with mixed cancers, Quinten et al 29 investigated the extent to which patients' and clinicians' symptom ratings contributed toward the estimation of OS. They found that both clinicians' and patients' scorings contributed independently and positively to the predictive accuracy of survival. 29 In addition, major clinical benefits, including better HRQOL and fewer hospitalizations and emergency room visits, as well as superior qualityadjusted survival, were demonstrated in a randomized controlled trial investigating the value of systematic Web data collection of patient-reported symptoms versus usual care. 30 Finally, the prominent role of patient self-report of symptoms in clinical research has been documented by the recent development of the National Cancer Institute's PRO-Common Terminology Criteria for Adverse Events, which points out the central role of the patient's voice in health care management. 31 The current study has limitations. We could not perform an external validation of this new index in a sample of newly diagnosed patients with untreated MDS given the lack of QOL research in patients with MDS, 32 which has limited the availability of similar data sets in this area.
However, we noted that our additional analysis of patients included in the independent cohort demonstrated that the novel FA-IPSS(h) index performed similarly well in both subgroups of pretreated and untreated patients. Indeed, it distinguished 3 risk group categories with distinct median OS rates in both subgroups. Next, it should be noted there is a revised version of the IPSS (ie, IPSS- R) 33 and further research is needed in this area. In our previous work, we found that self-reported fatigue is indeed independently associated with OS beyond the IPSS-R and that it also is weakly correlated with hemoglobin levels. 6 However, more in-depth analyses are needed to ascertain whether the inclusion of self-reported fatigue also may be integrated successfully into the IPSS-R index to further increase its prognostic accuracy. The current study also has notable strengths. We developed a prognostic tool that can be implemented easily and inexpensively in clinical practice and that also possibly could enhance a more patient-centered approach during the initial diagnostic workup. In addition, unlike many other studies in this area that used secondary data analyses, the current study was specifically designed and adequately powered to test the prognostic value of fatigue severity for survival. Patients also were recruited in a multicenter and international observational setting, lending further credit to the generalizability of the current study findings to patients typically seen in clinical practice. Finally, the FA-IPSS(h) index outperformed the original IPSS index both in the development and independent cohorts, and validation data were independently collected and analyzed.
The results of the current study demonstrate how self-reported fatigue can be implemented successfully into a well-established laboratory risk classification, thereby enabling a more accurate survival prediction in patients with advanced MDS, either untreated or pretreated. The FA-IPSS(h) index is an additional prognostic tool that might enhance clinicians' ability to provide more personalized treatment strategies. The current analysis offers a model for the integration of PROs into prognostic systems for patients with other cancers and advanced illnesses. Original Article
